Myovant Sciences Ltd.
(NYSE : MYOV)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.93%204.771.3%$443.81m
BIIBBiogen Inc.
0.04%225.851.3%$382.43m
GILDGilead Sciences, Inc.
1.44%65.440.9%$367.48m
CELGCelgene Corporation
0.70%101.091.3%$354.83m
ILMNIllumina, Inc.
0.20%310.923.5%$267.21m
REGNRegeneron Pharmaceuticals, Inc.
-0.45%304.072.6%$218.76m
EXASExact Sciences Corporation
4.90%99.5024.1%$209.16m
ALXNAlexion Pharmaceuticals, Inc.
2.68%104.062.0%$185.92m
VRTXVertex Pharmaceuticals Incorporated
1.47%176.141.9%$181.45m
AAgilent Technologies, Inc.
0.91%75.871.6%$155.18m
SRPTSarepta Therapeutics, Inc.
1.55%87.0314.6%$143.92m
ALDRAlder Biopharmaceuticals, Inc.
-0.11%18.9010.2%$132.19m
BMRNBioMarin Pharmaceutical Inc.
1.80%68.454.3%$97.68m
ACADACADIA Pharmaceuticals Inc.
1.76%40.1813.4%$91.16m
NKTRNektar Therapeutics
8.63%17.245.5%$85.51m

Company Profile

Myovant Sciences, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of women's health and endocrine diseases. The company's product includes relugolix, which is an oral, once-daily and small molecule that acts as a GnRH receptor antagonist. It also develops MVT-602 a kisspeptin agonist for the treatment of female infertility. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.